National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer
- PMID: 8604906
- PMCID: PMC1235114
- DOI: 10.1097/00000658-199603000-00006
National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer
Abstract
Background: The Commission on Cancer of the American College of Surgeons conducted a large, national survey to assess methods of diagnosis, American Joint Commission on Cancer staging, treatment, and outcome of patients with adenocarcinoma of the pancreas.
Study design: The survey questionnaire contained 160 questions and covered two study periods, 1983 to 1985 and 1990, for time-trend analysis. Nine hundred seventy-eight institutions throughout the United States voluntarily participated, contributing 8917 case reports for 1983 to 1985 and 8025 reports for 1990, resulting in a total of 16,942 patient reports. Most, but not all, of the participating hospitals maintain approval status with the Commission on Cancer of the American College of Surgeons.
Results: The ratio of male-to-female cases was 1:1. Patient characteristics including age, ethnicity, neighborhood income, type of insurance coverage, and hospital characteristics--including annual caseload and type of facility (e.g., teaching, community)--appeared to influence surgical multimodality treatment patterns. The most common presenting symptom was abdominal pain. The reported history of smoking for these patients with pancreatic cancer was higher than U.S. population averages. The frequency of using abdominal computed tomography scans, endoscopic retrograde cholangiopancreatography, carcinoembryonic antigen, and CA 19-9 during patient evaluation all increased. Time trends toward lower operative mortality and more extirpative surgery were reported, as was a slightly higher survival for those patients who were resected surgically.
Conclusions: Pancreatic cancer continues to be a disease of older patients. There were slight improvements in operative mortality. For a highly selective category of patients, cancer-directed surgery offers a chance for cure with excellent operative mortality and acceptable complication rates, especially when performed in institutions that have a 20 or greater case per year experience.
Similar articles
-
Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database.J Am Coll Surg. 1999 Jul;189(1):1-7. doi: 10.1016/s1072-7515(99)00075-7. J Am Coll Surg. 1999. PMID: 10401733
-
The National Cancer Data Base report on pancreatic cancer.Cancer. 1995 Nov 1;76(9):1671-7. doi: 10.1002/1097-0142(19951101)76:9<1671::aid-cncr2820760926>3.0.co;2-r. Cancer. 1995. PMID: 8635074
-
Regional variation in the treatment of pancreatic adenocarcinoma: Decreasing disparities with multimodality therapy.Surgery. 2017 Aug;162(2):275-284. doi: 10.1016/j.surg.2017.03.009. Epub 2017 May 6. Surgery. 2017. PMID: 28487044
-
Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base.HPB (Oxford). 2016 Jan;18(1):21-8. doi: 10.1016/j.hpb.2015.07.009. Epub 2015 Dec 21. HPB (Oxford). 2016. PMID: 26776847 Free PMC article. Review.
-
Progress in the diagnosis and treatment of pancreatic cancer--the Kyoto University experience.Hepatogastroenterology. 1989 Dec;36(6):431-6. Hepatogastroenterology. 1989. PMID: 2693297 Review.
Cited by
-
A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer.Gastrointest Cancer Res. 2012 May;5(3):77-83. Gastrointest Cancer Res. 2012. PMID: 22888387 Free PMC article.
-
Limited value of positron emission tomography in treatment of pancreatic cancer: surgeon's view.World J Surg. 2001 Sep;25(9):1134-9. doi: 10.1007/BF03215860. World J Surg. 2001. PMID: 11571948 Clinical Trial.
-
Establishment and characterization of a new transplantable pancreatic cancer xenograft (PZX-5) in immunosuppressed mice.Int J Pancreatol. 1998 Feb;23(1):51-62. doi: 10.1007/BF02787503. Int J Pancreatol. 1998. PMID: 9520091
-
Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.Oncotarget. 2016 Nov 1;7(44):71937-71950. doi: 10.18632/oncotarget.12433. Oncotarget. 2016. PMID: 27713122 Free PMC article.
-
Critical role of extracellular signal-regulated kinase (ERK) phosphorylation in novel vitamin K analog-induced cell death.Jpn J Cancer Res. 2000 Dec;91(12):1250-7. doi: 10.1111/j.1349-7006.2000.tb00911.x. Jpn J Cancer Res. 2000. PMID: 11123423 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical